Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 23, 2014
Technology Networks
 
Register | Sign in
Home Page>News

  News Archive

Galapagos Presents Favorable Phase 1 Data for IBD Target
Tuesday, October 21, 2014
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.

Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Tuesday, October 21, 2014
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.

Bioequivalence and Oral Drug Formulation Events
Monday, October 20, 2014
Simplifying the bioequivalence testing process and optimizing oral formulation development via unifying the global life science community this November in San Diego.

InSphero Wins ACES Award as Top European Academic Enterprise in Life Sciences
Wednesday, October 15, 2014
Second honor in three weeks continues momentum for leading supplier of 3D microtissues for in vitro toxicity and efficacy testing.

Auspherix and Domainex Announce Collaboration
Wednesday, October 15, 2014
Collaboration to develop new drugs to treat antibiotic-resistant bacterial infections.

Getting Metabolism Right
Thursday, October 09, 2014
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.

MIMETAS Raises 5.2 Million Dollar For Organ-on-a-Chip
Thursday, October 09, 2014
MIMETAS B.V. has raised 5.2 million Dollar to fund its expansion as a global leader in organ-on-a-chip technology.

Persistent Pharmacokinetic Challenges to Pediatric Drug Development
Wednesday, October 08, 2014
Current knowledge of rational drug dose adjustments is limited, greater effort needs to be made to determine ontogenic factors that influence ADME.

nLife Therapeutics Receives USD 350,000 from The Michael J. Fox Foundation
Tuesday, October 07, 2014
The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 2353
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv